NasdaqCM - Nasdaq Real Time Price USD

Nexalin Technology, Inc. (NXL)

1.1900

-0.0600

(-4.80%)

At close: May 13 at 4:00:01 PM EDT

Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data

HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the reconstitution of its Scientific Advisory Board (SAB) with the appointment of three renowned experts in neurology, neuroimaging, and neurodegenerative diseases. This move reflects Nexalin’s strategic prioritization of Alzheimer’s disease within its broader clinical development pipel

GlobeNewswire 22 hours ago

NXL
-4.80%

NXLIW
Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the closing of its previously announced underwritten public offering of 3,850,000 shares of its common stock at a public offering price of $1.30 per share. The gross proceeds from the offering to Nexalin were approximately $5.0 million, before deducting underwriting discounts and commissio

GlobeNewswire 7 days ago

NXL
-4.80%

NXLIW
Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

HOUSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the pricing of an underwritten public offering of 3,850,000 shares of its common stock at a price to the public of $1.30 per share. The gross proceeds from the offering to Nexalin are expected to be approximately $5.0 million, before deducting underwriting discounts and commissions and oth

GlobeNewswire 8 days ago

NXL
-4.80%

NXLIW
Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

Company initiates formal regulatory engagement on trial design for Alzheimer’s, dementia, and MCI indicationsHOUSTON, TX, May 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), today announced that it plans to submit a Q-Submission (“Q-Sub”) to the U.S. Food and Drug Administration (FDA) related to its Gen-2 SYNC system. This regulatory milestone is intended to facilitate structured dialogue with the FDA regarding clinical trial design for th

GlobeNewswire 12 days ago

NXL
-4.80%

NXLIW
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

HOUSTON, TX, April 24, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that its proprietary Gen-2 neurostimulation device has received institutional review board (IRB) approval in Brazil for a new clinical trial evaluating its use in the treatment of anxiety disorders and chronic insomnia. The study will be conducted at the Instituto de Psiquiatria do Ho

GlobeNewswire 19 days ago

NXL
-4.80%

NXLIW
Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™HOUSTON, TX, April 23, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the successful completion and launch of phases one through five of its proprietary virtual clinic and digital research ecosystem. The launch of Nexalin’s virtual clin

GlobeNewswire 20 days ago

NXL
-4.80%

NXLIW
Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

Proposed bipartisan legislation would expand Medicare reimbursement pathways for AI-enabled medical devices — a framework that supports Nexalin’s Gen-3 HALO Clarity™ neurostimulation device integrated with artificial intelligenceHOUSTON, TX, April 21, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced its support for the Health Tech Investment Act (S. 1399)

GlobeNewswire 22 days ago

NXL
-4.80%

NXLIW
Nexalin secures patent on brain stimulation method for substance use disorders

Nexalin’s method aims to treat substance use disorders by stimulating neural pathways linked to addiction and withdrawal symptoms.

Medical Device Network 29 days ago

NXLIW
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

Patent Approval Reinforces Nexalin’s Leadership in Non-Invasive Brain Stimulation for Addiction TreatmentHOUSTON, TX, April 14, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is pleased to announce that the United States Patent and Trademark Office (USPTO) has officially granted its patent titled "Alternating Current Dynamic Frequency Stimulation Method for Opioid Use

GlobeNewswire 29 days ago

NXL
-4.80%

NXLIW
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has successfully enrolled the first patients in its clinical trial at the University of California, San Diego (UCSD), in collaboration with the VA San Diego Healthcare System (San Diego VA). The company began treatment of the first patients this week with the Nexalin HALO™. Th

GlobeNewswire last month

NXL
-4.80%

NXLIW
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3

Houston, TX, March 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) is pleased to invite investors to a webinar on April 3, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic mod

GlobeNewswire last month

NXL
-4.80%

NXLIW
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESS Newswire / March 14, 2025 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program ...

ACCESS Newswire last month

NXL
-4.80%

NXLIW

CLDI
Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

Patent Strengthens Nexalin’s Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids, Alcohol, Cocaine and MethamphetamineHOUSTON, TX, March 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has received a Notice of Allowance from the United States Patent and Trad

GlobeNewswire 2 months ago

NXL
-4.80%

NXLIW
UCSD begins trial with Nexalin’s Halo Clarity device for mTBI and PTSD

As the trial advances, an additional 40-50 devices will be delivered.

Medical Device Network 2 months ago

NXLIW
Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval

HALO™ Clarity Devices Successfully Shipped for First Phase of Clinical TrialsHOUSTON, TX, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that following Institutional Review Board (IRB) approval, the University of California, San Diego (UCSD) has received the first shipment of HALO™ Clarity devices to commence its clinical trial evaluating the t

GlobeNewswire 2 months ago

NXL
-4.80%

NXLIW
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

HOUSTON, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is honored to announce that General Wesley K. Clark (Ret.), former NATO Supreme Allied Commander Europe, has joined its Military & Government Advisory Board. General Clark will collaborate with esteemed members David F. Lasseter, former Deputy Assistant Secretary of Defense for Policy, and William A.

GlobeNewswire 2 months ago

NXL
-4.80%

NXLIW
Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

HOUSTON, TX, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces that it has received Institutional Review Board (IRB) approval from the University of California, San Diego (UCSD) for clinical testing of its HALO™ Clarity (HALO) headset in human subjects. This study is being conducted independently by UCSD. Nexalin is providing the HALO devices for resear

GlobeNewswire 2 months ago

NXL
-4.80%

NXLIW
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

HOUSTON, TEXAS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces its appointment as Industry Co-Chair of the National Traumatic Brain Injury (TBI) Registry Coalition. This appointment emphasizes Nexalin's commitment to advancing TBI advocacy and research, particularly in collaboration with policymakers and stakeholders in Washington, D.C. "We are honor

GlobeNewswire 2 months ago

NXL
-4.80%

NXLIW
Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

HOUSTON, TX, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces the publication of a landmark study in the Journal of Affective Disorders demonstrating the potential efficacy of its proprietary DIFS technology. The research highlights the potential of DIFS to deliver meaningful reductions in systolic and diastolic blood pressure in patients with major de

GlobeNewswire 3 months ago

NXL
-4.80%

NXLIW
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23

HOUSTON, TX, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar today, January 23, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clin

GlobeNewswire 3 months ago

NXL
-4.80%

NXLIW

Performance Overview

Return	NXL	S&P 500 (^GSPC)
YTD	-56.88%	+0.08%
1-Year	-3.88%	+12.74%
3-Year	-55.93%	+46.29%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Nexalin Technology, Inc. (NXL)

Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

Nexalin secures patent on brain stimulation method for substance use disorders

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

UCSD begins trial with Nexalin’s Halo Clarity device for mTBI and PTSD

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23

Performance Overview